XTL Biopharmaceuticals Ltd.
- XTLB
- NASDAQ
- Biotechnology
- Biotech
- Healthcare
$1.83
Today −6.63%Quote Oct 19, 2026, 04:52 PM UTC
−18.33%over the last month
Max drawdown −22.0%From 1-month high −18.7%3 months −32.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
10
Market value
$1.73B
Quote Oct 19
Floor
$1.71
6.4% below price
Resistance
$1.85
1.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about XTLBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free